NovoCure (NVCR) EBT Growth (1y) (2015 - 2026)
NovoCure (NVCR) EBT Growth (1y) (2015 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 199.44 Bn | 193.84 Bn | 7.27 Bn | -29.12% |
| 2 | Stryker | 127.32 Bn | 123.85 Bn | 4.50 Bn | 53.94% |
| 3 | Medtronic | 118.87 Bn | 109.65 Bn | 6.41 Bn | 45.44% |
| 4 | Boston Scientific | 73.47 Bn | 72.93 Bn | 3.85 Bn | 12.65% |
| 5 | Edwards Lifesciences | 51.90 Bn | 47.65 Bn | 1.35 Bn | 29.89% |
| 6 | Dexcom | 34.30 Bn | 32.36 Bn | 830.00 Mn | 31.69% |
| 7 | GE HealthCare Technologies | 33.74 Bn | 31.63 Bn | 2.18 Bn | 13.05% |
| 8 | Koninklijke Philips | 26.35 Bn | 23.03 Bn | 4.55 Bn | 71.38% |
| 9 | Steris | 23.05 Bn | 22.56 Bn | 684.20 Mn | 17.94% |
| 10 | NovoCure | 2.05 Bn | 1.61 Bn | 142.48 Mn | 64.40% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 64.40% |
| Mar 31, 2026 | -128.61% |
| Dec 31, 2025 | 25.82% |
| Sep 30, 2025 | -39.09% |
| Jun 30, 2025 | -53.90% |
| Mar 31, 2025 | 4.26% |
| Dec 31, 2024 | -43.27% |
| Sep 30, 2024 | 55.24% |
| Jun 30, 2024 | 57.83% |
| Mar 31, 2024 | 38.05% |
| Dec 31, 2023 | -18.35% |
| Sep 30, 2023 | -105.93% |
| Jun 30, 2023 | -130.79% |
| Mar 31, 2023 | -1,931.01% |
| Dec 31, 2022 | -27.31% |
| Sep 30, 2022 | -122.32% |
| Jun 30, 2022 | -76.47% |
| Mar 31, 2022 | 8.01% |
| Dec 31, 2021 | -389.78% |
| Sep 30, 2021 | -195.42% |